Search clinical trials for: MK-1942

Total 1795 results

Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Treatment Resistant Depression

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom, South Africa
Merck Sharp & Dohme LLC

Terminated

Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)

HIV-1 Infection
Merck Sharp & Dohme LLC

Not yet recruiting

Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)

Systolic Dysfunction
Merck Sharp & Dohme LLC
Bayer; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)

Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

Chronic Heart Failure With Reduced Ejection Fraction

China, United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, New Zealand, Peru and more
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

Alzheimer's Disease

United States, Argentina, Australia, Canada, Colombia, Italy, Japan, Korea, Republic of, New Zealand, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (DDI)

Alzheimer's Disease

United States
Sorrento Therapeutics, Inc.

Recruiting

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Newsoara Biopharma Co., Ltd.

Recruiting

Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

T2DM (Type 2 Diabetes Mellitus)

China
Advaxis, Inc.
Merck Sharp & Dohme LLC

Completed

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Cancer | Prostate Cancer

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Early Phase 2 Clinical Study of TS-142 in Patients With Insomnia Disorder

Insomnia Disorder

Japan
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

Healthy
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Study of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.

Patients With Mild Obstructive Sleep Apnea Hypopnea

Japan
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Bladder Urothelial Cancer

China
Taisho Pharmaceutical Co., Ltd.

Completed

Late Phase II Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
IconOVir Bio

Recruiting

Safety and Tolerability of Intravenous Administration of ICVB-1042

Patients With Advanced Solid Tumors

United States
Taisho Pharmaceutical R&D Inc.

Completed

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Healthy Volunteers

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Phase III Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Healthy Volunteer

Japan
Clinique Pasteur

Recruiting

Study on Treatment of Varicose Veins by Endovenous Laser (1940 nm vs 1470 nm) (NEWWAVE)

Varicose Veins

France
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, France
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Candela Corporation
Miami Dermatology and Laser Institute

Completed

Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions

Pigmented Skin Lesion

United States
ModernaTX, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

Prevention of Chikungunya Virus Infection

United States
PreCision Dermatology, Inc.

Completed

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

Healthy Volunteer

Japan
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia, India
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor

China
Vidya Raman

Completed

Investigating Reaction Time Among Children Who Snore

Snoring

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Bristol-Myers Squibb

Completed

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) (MDX1342-02)

Chronic Lymphocytic Leukemia

United States
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Taisho Pharmaceutical Co., Ltd.

Completed

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

Healthy Volunteer

Japan
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States

3

Subscribe